Guntram Schernthaner
Overview
Explore the profile of Guntram Schernthaner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
4471
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saely C, Schernthaner G, Brix J, Klauser-Braun R, Zitt E, Drexel H, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):147-156.
PMID: 37101036
Hypertension is one of the most important comorbidities of diabetes, contributing significantly to death and leading to macrovascular and microvascular complications. When assessing the medical priorities for patients with diabetes,...
2.
Lechleitner M, Kaser S, Hoppichler F, Roden M, Weitgasser R, Ludvik B, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):98-105.
PMID: 37101030
This guideline summarizes diagnosis of type 1 diabetes, including accompanying autoimmune disorders, insulin therapy regimens and glycemic target values.
3.
Lechleitner M, Roden M, Weitgasser R, Ludvik B, Fasching P, Hoppichler F, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):45-52.
PMID: 37101024
The present article is a recommendation of the Austrian Diabetes Association for the practical use of injection therapy (GLP1-receptor agonists and insulin) in type 2 diabetes.
4.
Clodi M, Abrahamian H, Brath H, Schernthaner G, Brix J, Ludvik B, et al.
Wien Klin Wochenschr
. 2023 Apr;
135(Suppl 1):32-44.
PMID: 37101023
Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy...
5.
Schernthaner G, Brand K, Bailey C
Metabolism
. 2022 Feb;
130:155160.
PMID: 35143848
Metformin has been in clinical use for the management of type 2 diabetes for more than 60 years and is supported by a vast database of clinical experience: this includes...
6.
Rossing P, Filippatos G, Agarwal R, Anker S, Pitt B, Ruilope L, et al.
Kidney Int Rep
. 2022 Jan;
7(1):36-45.
PMID: 35005312
Introduction: FIDELIO-DKD (FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease) investigated the nonsteroidal, selective mineralocorticoid receptor (MR) antagonist finerenone in patients with CKD and type 2...
7.
The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
Czupryniak L, Dicker D, Lehmann R, Prazny M, Schernthaner G
Cardiovasc Diabetol
. 2021 Oct;
20(1):198.
PMID: 34598700
Patients with Covid-19 place new challenges on the management of type 2 diabetes, including the questions of whether glucose-lowering therapy should be adjusted during infection and how to manage a...
8.
9.
Schernthaner G
Lancet Diabetes Endocrinol
. 2021 Apr;
9(5):251-252.
PMID: 33798462
No abstract available.
10.
Herz C, Brix J, Ludvik B, Schernthaner G, Schernthaner G
Obes Surg
. 2021 Feb;
31(6):2545-2550.
PMID: 33538983
Purpose: Dipeptidyl peptidase 4 (DPP4) is expressed and secreted by adipocytes. DPP4 induces insulin resistance independently of its effect on glucagon-like peptide 1, thus it is conceivable that DPP4 directly...